Oral Low Doses Tolerance INduction Study for Peanuts

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · May 10, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients evaluated at the Montpellier University Hospital, Allergy Unit ;
• • Patients aged 5 years or older;
• • Patients with a history of immediate reaction after consuming peanuts
• • AND a positive peanut prick test;
• • AND peanut positive specific serum IgE (ImmunoCAP®);
• • AND a positive oral peanut challenge test OR a clinical history of anaphylaxis AND peanut-specific IgE\> 100 kUA / L (ImmunoCAP®);
• • Patients who started peanut OIT between September 2018 and January 2021.
• Exclusion criteria:
• • Patients in exclusion period determined by a previous study;
• • Patients under legal protection, under guardianship or under curatorship;
• • Possible poor therapeutic compliance to the OIT protocol;
• • Active malignant neoplasia or autoimmune disease;
• • Active eosinophilic esophagitis or other gastrointestinal eosinophilic disorders;
• • Severe active eczema;
• • Pregnancy ;
• • Cardiovascular disease and use of beta blockers and / or ACE inhibitors;
• • Chronic urticaria;
• • Mastocytosis.